ரிச்சர்ட் டலொக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரிச்சர்ட் டலொக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரிச்சர்ட் டலொக் Today - Breaking & Trending Today

Investegate |Metal Tiger plc Announcements | Metal Tiger plc: Execution of Share Purchase Agreement


Execution of Share Purchase Agreement
Metal Tiger plc (AIM: MTR), the London Stock Exchange AIM listed investor in natural resource opportunities, is pleased to announce that Cobre Limited (“Cobre”) and the shareholders of Kalahari Metals Limited (“KML”) (the “KML Vendors”) (together the “Parties”) have executed a Share Purchase Agreement (the “SPA”) in respect of the conditional acquisition by Cobre of 51% of the issued share capital of KML (the “Transaction”).
The terms of the SPA are generally consistent with the binding Heads of Agreement previously entered into by the Parties, as announced by Metal Tiger on 24 August 2020, 22 October 2020 and 20 November 2020. Metal Tiger is one of the KML Vendors and currently has a 62.17% equity interest in KML. In addition, Metal Tiger currently holds an 18.79% equity interest in Cobre. ....

City Of , United Kingdom , Botswana General , Western Australia , Paul Shackleton , James Crothers , Hugo Liddy , Richard Tulloch , Gordon Poole , Keith Johnston , Mark Potter , Michael Mcneilly , Jack Botros , James Dance , Steve Douglas , Cobre Limited , London Stock Exchange , Metal Tiger , Kalahari Metals Limited , Strand Hanson Limited Nominated Adviser , Kitlanya Proprietary Limited The , Kalahari Metals , Triprop Holdings Pty Limited , Sandfire Resources Limited , Cobre Kalahari Pty Ltd , Share Purchase Agreement ,

TYK2 Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 and as an Important Potential Target for Therapy


Search jobs
14-Dec-2020
TYK2 Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 and as an Important Potential Target for Therapy
Findings published in
Nature support scientific rationale for Sareum’s SDC-1801 development programme in Covid-19 and its recent grant award from UKRI
Cambridge, UK, 14 December 2020 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to note that a multi-centre analysis of DNA samples from patients with severe forms of Covid-19, including symptoms caused by the over-active inflammatory response (“cytokine storm”), has identified TYK2 as a key causative genetic mechanism and a potential target for therapy. ....

United Kingdom , City Of , Tim Mitchell , John Beresford Peirse , Richard Tulloch , Citigate Dewe Rogerson , United Kingdom Research Innovation , London Stock Exchange , Strand Hanson Limited Nominated Adviser , Sierra Oncology Inc , Cancer Research United Kingdom , Institute Of Cancer Research , Pioneer Fund , Sareum Holdings , Accelerated Article Preview , United Kingdom Research , Nature Article Preview , Hanson Limited , Nominated Adviser , Nominated Broker , Dewe Rogerson , David Dible , Acute Respiratory Distress Syndrome , Interferon Type , Cancer Research , Cancer Research United ,